given the large percentage of share prices increased (+84% yesterday and +71% today) and the record trading volume (a total nearly 80 mil shares traded in 2 days), I really hope you guys recognize the significance of the released data in the conference yesterday:
The 2 key information from the presentation which can help us to come up with a reasonable estimation for OCRX valuation: - OCR-002 is more effective and FDA should look into having Rifaximin to be replaced with OCR-002 (on slices #25, #26 and #27). - Rifaximin 2016 revenue was $932M (on slide #5)
So once OCR-002 is replacing Rifaximin, let's take a very conservative figure of revenue for OCR-002 = 2/3 of Rifaximin actual revenue or = $932M * 2/3 = $621M
According to CSI market, the price to sales (TTM) ratio in the last 4 quarters for Biotech & Drugs industry are: 1.7 (low) and 4.69 (high) (detailed info can be found via this link )
With $621M revenue, a reasonable OCRX marketcap should be in the range: $621M x 1.7 and $621M x 4.69 or between: $1055M and $2912M And given the existing number of outstanding shares = 23M shares, OCRX share price should be range: $46 -> $126/share, once FDA approve OCR-002 replacing Rifaximin.
I'm in for long-term and will keep my shares for at least a year.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.